Inclusion Criteria:  Subject has ≥ 18 years and ≤ 80 years Subject has a VAS ≥ 5 Subject has refractory chronic lower limbs neuropathic pain (e.g. diabetic foot peripheral neuropathy, foot peripheral neuropathy, ankle peripheral neuropathy) or/and neuropathic back pain for at least 6 months Subject has stable pain for at least 30 days Pain medication(s) dosage(s) is/are stable for at least 30 days Subject is refractory to other treatment modalities (e.g. Medication, psychological therapies, pain interventions, surgery) Subject is eligible for SCS after a pre-implantation assessment by a multidisciplinary team, as described by the French National Authority for Health Subject understands and accepts constraints of the study. Patient covered by French national health insurance. Subject has given written consent to the study after having received clear and complete information  Non inclusion criteria:  Subject has a coagulation disorder Subject is or has been treated with SCS, subcutaneous or peripheral nerve stimulation, an intrathecal drug delivery system Subject has had corticosteroid therapy within the past 30 days Subject has had radiofrequency therapy within the past 3 months Subject has been diagnosed with cancer in the past 2 years Subject has had a spinal surgery within the past 6 months Subjects requiring closer protection, i.e. minors, pregnant women, nursing mothers, subjects deprived of their freedom by a court or administrative decision, subjects admitted to a health or social welfare establishment, major subjects under legal protection, and finally patients in an emergency setting Simultaneous participation to any interventional study on health product or any study able to interfere with the current study endpoints. Pregnant or breastfeeding women, women at age to procreate and not using effective contraception Brain MRI contraindication